ACTIVE_NOT_RECRUITING

Integrated Care and Treatment for Severe Infectious Diseases and Substance Use Disorders Among Hospitalized Patients

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to test the effectiveness of an integrated infectious disease/substance use disorder (SUD) clinical team intervention approach in patients hospitalized with severe injection-related infections (SIRI) who use drugs. The main question this study aims to answer is whether this intervention approach will be associated with lower mortality and fewer hospital readmissions. Participants will participate in the integrated SUD/ID care team intervention (SIRI Team). Researchers will compare this intervention to treatment as usual (TUA) to see if there are any differences in health outcomes.

Official Title

Integrated Care and Treatment for Severe Infectious Diseases and Substance Use Disorders Among Hospitalized Patients

Quick Facts

Study Start:2024-01-05
Study Completion:2027-04-03
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT05688423

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Be admitted to a participating hospital at the time of randomization
  2. * Be 18 years of age or older
  3. * Currently be experiencing a severe injection-related infection/SIRI or suspected SIRI
  4. * Have an indication of injecting drugs in the prior year
  5. * Provide informed consent
  6. * Ability to communicate in English
  7. * Provide sufficient locator information
  8. * Sign a HIPAA form and/or EHR release to facilitate record abstraction
  9. * Report being willing to return for follow-up visits
  1. * have significant cognitive or developmental impairment to the extent that they are unable to provide informed consent
  2. * (or their legal guardian/representative) are unable or unwilling to give written informed consent
  3. * are currently in jail, prison or other overnight facility as required by court of law or have pending legal action that could prevent participation in study activities
  4. * are terminated via site principal investigator decision with agreement from one of the study lead investigators.

Contacts and Locations

Principal Investigator

Lisa R Metsch, PhD
PRINCIPAL_INVESTIGATOR
Columbia University
David P Serota, MD, MSc
PRINCIPAL_INVESTIGATOR
University of Miami
Daniel J Feaster, PhD
PRINCIPAL_INVESTIGATOR
University of Miami
Carlos del Rio, MD
PRINCIPAL_INVESTIGATOR
Emory University

Study Locations (Sites)

University of Alabama at Birmingham
Birmingham, Alabama, 35294
United States
University of Miami - Jackson Memorial Hospital
Miami, Florida, 33136
United States
Tampa General Hospital
Tampa, Florida, 33601
United States
University of New Mexico Health Sciences Center
Albuquerque, New Mexico, 87106
United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States
University of Utah Hospital
Salt Lake City, Utah, 84132
United States

Collaborators and Investigators

Sponsor: Columbia University

  • Lisa R Metsch, PhD, PRINCIPAL_INVESTIGATOR, Columbia University
  • David P Serota, MD, MSc, PRINCIPAL_INVESTIGATOR, University of Miami
  • Daniel J Feaster, PhD, PRINCIPAL_INVESTIGATOR, University of Miami
  • Carlos del Rio, MD, PRINCIPAL_INVESTIGATOR, Emory University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-01-05
Study Completion Date2027-04-03

Study Record Updates

Study Start Date2024-01-05
Study Completion Date2027-04-03

Terms related to this study

Keywords Provided by Researchers

  • substance use disorders
  • severe injection-related infections
  • randomized controlled trial
  • hospital-based care
  • harm reduction

Additional Relevant MeSH Terms

  • Injection Site Infection
  • Substance Use Disorders